|MDACC Study No:||2011-0229 (clinicaltrials.gov NCT No: NCT00953420)|
|Title:||Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients with Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma (CADEN)|
|Principal Investigator:||Bonnie S. Glisson|
|Treatment Agent:||Carboplatin; Docetaxel; Modified T-cells|
|Study Description:||The goal of this clinical research study is to learn how relapsed or refractory |
EBV-associated NPC tumors respond when treated with carboplatin and docetaxel
followed by EBV-specific cytotoxic T cells (EBV-CTLs). The safety and
effectiveness of study drugs will also be studied.
EBV-CTLs are a type of white blood cell. The cells are changed to recognize and
attack EBV infected cells.
Carboplatin is designed to interfere with the growth of cancer cells by
stopping cell division, which may cause the cells to die.
Docetaxel is designed to stop the growth of cancer cells, which may cause the
cells to die. It is believed to be weakly effective at killing blood vessels
in tumor tissue as well.